Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that is developed as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was incorporated in 2009 and is based in LA Jolla, California.

GRI Bio, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DESIGNATION HIGHLIGHTS SIGNIFICANT REGULATORY MILESTONE AND PROVIDES A POTENTIAL PATHWAY TO SEVEN YEARS OF U.S. MARKET EXCLUSIVITY

GRI BIO SECURES FDA ORPHAN DRUG DESIGNATION FOR GRI-0621 (TAZAROTENE) IN IDIOPATHIC PULMONARY FIBROSIS

LIVE WEBCAST FIRESIDE CHAT WITH MARC HERTZ, PHD, CHIEF EXECUTIVE OFFICER, ON WEDNESDAY, MAY 20, 2026 REGISTER FOR THE EVENT HERE LA JOLLA, CA, MAY 18, 2026 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) (GRI BIO OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF NATURAL KILLER T (NKT) CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT MARC HERTZ, PHD, CHIEF EXECUTIVE OFFICER OF GRI BIO, WILL PARTICIPATE IN A FIRESIDE CHAT AT A.G.P.'S ANNUAL HEALTHCARE COMPANY SHOWCASE BEING HELD VIRTUALLY ON WEDNESDAY, MAY 20, 2026.

GRI BIO TO PRESENT AT A.G.P.'S ANNUAL HEALTHCARE COMPANY SHOWCASE

LIVE WEBCAST FIRESIDE CHAT WITH MARC HERTZ, PHD, CHIEF EXECUTIVE OFFICER, ON WEDNESDAY, MAY 20, 2026 REGISTER FOR THE EVENT HERE LA JOLLA, CA, MAY 18, 2026 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) ("GRI BIO" OR THE "COMPANY"), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF NATURAL KILLER T ("NKT") CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT MARC HERTZ, PHD, CHIEF EXECUTIVE OFFICER OF GRI BIO, WILL PARTICIPATE IN A FIRESIDE CHAT AT A.

GRI BIO TO PRESENT AT A.G.P.S ANNUAL HEALTHCARE COMPANY SHOWCASE

PHASE 2A DATA SHOW ZERO COUGH AND 60% LOWER TREATMENT-RELATED DIARRHEA THAN PLACEBO DESPITE HIGHER NINTEDANIB USE IN THE ACTIVE ARM  SUGGESTING GRI-0621 MAY MITIGATE NINTEDANIB-RELATED GI-TOXICITIES WHEN USED IN COMBINATION

GRI BIO REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS, NEW DATA REINFORCING DIFFERENTIATED PROFILE OF GRI-0621 IN IDIOPATHIC PULMONARY FIBROSIS AND HIGHLIGHTS CONTINUED ADVANCEMENT OF DIFFERENTIATED IMMUNE-MODULATING PIPELINE

ISSUED CLAIMS FURTHER STRENGTHEN GLOBAL INTELLECTUAL PROPERTY PORTFOLIO SUPPORTING IMMUNE CELL MODULATION PLATFORM AND EXPAND STRATEGIC PRESENCE IN A HIGH-GROWTH INTERNATIONAL MARKET

GRI BIO RECEIVES NOTICE OF ALLOWANCE FOR UAE PATENT APPLICATION COVERING NOVEL TYPE 2 DIVERSE NKT CELL AGONISTS FOR THE TREATMENT OF INFLAMMATORY CONDITIONS

GRI BIO CEO, MARC HERTZ, FEATURED IN VIRTUAL INVESTOR WHAT THIS MEANS SEGMENT

 LIVE VIDEO WEBCAST ON WEDNESDAY, FEBRUARY 11 TH AT 1:00 PM EST

GRI BIO TO PARTICIPATE IN THE CORPORATE CONNECT WEBINAR SERIES VIRTUAL CONFERENCE HOSTED BY WEBULL FINANCIAL

COMPANY REPORTED $8.2 MILLION IN CASH AND CASH EQUIVALENTS AT DECEMBER 31, 2025 AND RAISED ADDITIONAL $6.5 MILLION IN GROSS PROCEEDS IN JANUARY 2026

GRI BIO REITERATES FULL YEAR 2025 FINANCIAL RESULTS, STRENGTHENS BALANCE SHEET AND SUMMARIZES KEY RECENT HIGHLIGHTS

MULTIPLE INDEPENDENT MOLECULAR SIGNALS CONVERGE TO VALIDATE GRI-0621 AS A POTENTIAL DISEASE-MODIFYING THERAPY LA JOLLA, CA, JAN. 28, 2026 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) (GRI BIO OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF IMMUNE CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED ADDITIONAL POSITIVE DATA FROM ITS RECENTLY COMPLETED PHASE 2A CLINICAL STUDY OF GRI-0621 IN IDIOPATHIC PULMONARY FIBROSIS (IPF), FURTHER STRENGTHENING POTENTIAL CLINICAL PROOF-OF-CONCEPT AND REINFORCING THE THERAPEUTIC DIFFERENTIATION OF GRI-0621. NEWLY REPORTED RNA-SEQUENCING DIFFERENTIAL GENE EXPRESSION DATA DEMONSTRATE THAT TREATMENT WITH GRI-0621 RESULTED IN SIGNIFICANT IMPROVEMENT ACROSS GENES ASSOCIATED WITH LUNG INJURY, MYOFIBROBLAST ACTIVATION, EXTRACELLULAR MATRIX DEPOSITION, FIBROSIS PROGRESSION, AND ALVEOLAR BASEMENT MEMBRANE AND EPITHELIAL REPAIR COMPARED TO PLACEBO.

GRI BIO DELIVERS COMPELLING NEW PHASE 2A GENE EXPRESSION DATA DEMONSTRATING IMPROVEMENTS IN KEY DRIVERS OF FIBROSIS AND LUNG REPAIR IN IPF

GRI'S COMMON STOCK IS EXPECTED TO BEGIN TRADING ON A POST-SPLIT ADJUSTED BASIS ON JANUARY 26, 2026 LA JOLLA, CA, JAN. 21, 2026 (GLOBE NEWSWIRE) -- GRI BIO, INC. (NASDAQ: GRI) (GRI BIO OR THE COMPANY), A BIOTECHNOLOGY COMPANY ADVANCING AN INNOVATIVE PIPELINE OF IMMUNE CELL MODULATORS FOR THE TREATMENT OF INFLAMMATORY, FIBROTIC AND AUTOIMMUNE DISEASES, TODAY ANNOUNCED THAT THE BOARD OF DIRECTORS OF THE COMPANY APPROVED A1-FOR-28 REVERSE STOCK SPLIT (THE REVERSE SPLIT) OF THE COMPANY'S COMMON STOCK. THE REVERSE SPLIT WAS APPROVED BY THE STOCKHOLDERS OF THE COMPANY AT A SPECIAL MEETING OF THE COMPANY HELD ON JANUARY 15, 2026.

GRI Bio, Inc.

GRI

Price

Financial Reports

No items found.

Press Releases

GRI Bio, Inc.

GRI.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

GRI